>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Niraparib 尼拉帕尼; MK-4827

Niraparib (MK-4827) 是高效的，具有生物口服利用度的 PARP1 和 PARP2 抑制剂，IC50 分别为 3.8 nM 和 2.1 nM。Niraparib 抑制 DNA 损伤修复，诱导凋亡 (apoptosis) 并具有抗肿瘤活性。

货号：
TK0235
规格：

1mg

2mg

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	1038915-60-4
生物活性	Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.
分子式	C19H20N4O
分子量	320.39
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : 25 mg/mL (78.03 mM; Need ultrasonic)
体内研究	Niraparib (MK-4827) is well tolerated and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. Niraparib (MK-4827) is characterized by acceptable pharmacokinetics in rats with plasma clearance of 28 (mL/min)/kg, very high volume of distribution (Vdss=6.9 L/kg), long terminal half-life (t1/2=3.4 h), and excellent bioavailability, F=65%. Niraparib (MK-4827) enhances radiation response of p53 mutant Calu-6 tumor in both cases, with the single daily dose of 50 mg/kg being more effective than 25 mg/kg given twice daily.
体外研究	Niraparib (MK-4827) inhibits PARP activity with EC50=4 nM and EC90=45 nM in a whole cell assay. MK-4827 inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. MK-4827 displays excellent PARP 1 and 2 inhibition with IC50=3.8 and 2.1 nM, respectively, and in a whole cell assay. To validate that Niraparib (MK-4827) inhibits PARP in these cell lines, A549 and H1299 cells are treated with 1 μM MK-4827 for various times and measured PARP enzymatic activity using a chemiluminescent assay. The results show that Niraparib (MK-4827) inhibits PARP within 15 minutes of treatment reaching about 85% inhibition in the A549 cells at 1 h and about 55% inhibition at 1 h for the H1299 cells.
文献	•Cancer Discov. 2017 Sep;7(9):984-998. •Cancer Cell. 2020 Dec 14;38(6):844-856.e7. •J Clin Invest. 2019 Mar 1;129(3):1211-1228. •Theranostics. 2020 Jul 25;10(21):9477-9494. •Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. •Cancer Lett. 8 November 2021. •NPJ Precis Oncol. 2021 Jun 9;5(1):49. •EBioMedicine. 2020 Sep;59:102923. •Cell Death Dis. 2020 Apr 6;11(4):219. •Elife. 2021 Jun 23;10:e69454. •Int J Biol Sci. 2020 Feb 21;16(8):1363-1375. •Front Oncol. 2021 Jul 9;11:681441. •Carcinogenesis. 2020 May 14;41(3):345-357. •Mol Pharm. 2021 Nov 3. •Life Sci Alliance. 2021 Oct 5;4(12):e202101144. •J Mol Med (Berl). 2019 Aug;97(8):1183-1193. •Sci Rep. 2021 Sep 27;11(1):19138. •Appl Microbiol Biotechnol. 2019 Dec;103(23-24):9557-9568. •DNA Repair (Amst). 2019 Jan;73:64-70. •Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867. •Nucl Med Biol. 2016 Dec;43(12):752-758. •Patent. US20210299137A1. •HAL. archives-ouvertes. 2020 Dec 4. •Materials Today Bio. 2020 Oct 22;8:100082. •Patent. US20200148645A1 •Patent. US20200129476A1 •Patent. US20200078369A1 •medRxiv. 2020 Jan. •Faculty of Biology, University of Belgrade. 2019 Aug. •Patent. US20190092732A1. •Patent. US20180362972A1. •Patent. US20180134664A1. •Patent. US9932310B2. •Patent. US20170226063A1.
纯度及产品资料	98%

推荐产品